Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
The independent source for health policy research, polling, and news.
1,481 - 1,500 of 1,841 Results
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Dialysis companies are fighting a bill in the California legislature that could disrupt their business model. Their weapons: campaign cash and a sophisticated public relations campaign.
Before 鈥淢edicare for All,鈥 there was just Medicare, the federal program that provides insurance to 60 million Americans. This week, KHN鈥檚 Julie Rovner talks to Tricia Neuman of the Kaiser Family Foundation about how Medicare works and whom it serves. Then, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Kimberly Leonard of the Washington Examiner join Rovner to talk about some current Medicare issues being debated in Washington, D.C.
Americans routinely skirt federal law by crossing into Canada and Mexico or tapping online pharmacies abroad to purchase prescription medications at a fraction of the price they would pay at home. Is it safe? Not necessarily. Here鈥檚 some advice.
An encounter with a cat led to rabies shots and provided yet another illustration of how confusing, contrary and expensive the American health care system is.
The loss of the longtime hospital in Fort Scott, Kan., forces trauma patients to deal with changing services and expectations.
You asked about drug prices, the 鈥淐adillac tax鈥 on generous insurance plans and why Americans don鈥檛 know that most other countries also have combination public-private insurance systems. This week, Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico and Caitlin Owens of Axios join KHN鈥檚 Julie Rovner to answer those questions.
Critics worry the delays come at a steep cost: Medicare paying for millions of unnecessary exams and patients subject to radiation for no medical benefit.
States increasingly expect to see insurers enter or re-enter ACA marketplaces next year. That鈥檚 a critical sign that these exchanges are growing less risky for insurers despite ongoing political and legal battles over the ACA.
In the wake of the opioid crisis, the highly communicable hepatitis A virus is spreading in more than half the states and making its way into the general public. Underfunded health officials are valiantly trying to fight it with vaccines.
Medicare beneficiaries under observation care in the hospital can face higher costs for treatment and are not covered for nursing home care when discharged. A federal trial in Hartford, Conn., will determine whether the government鈥檚 ban on appeals involving observation care coverage is fair.
The patient is from Mississippi. The surgeon is from Wisconsin. They meet in a Mexican resort for knee replacement surgery. Because the care costs so much less than in the U.S, the patient鈥檚 health plan pays her $5,000.
Residents in Colorado ski resort country found relief from high insurance premiums and high hospital costs by joining forces and negotiating prices directly with the local hospital.
Tennessee's innovative Medicaid program is offering bonuses to mental health providers who help make sure their Medicaid patients get preventive help and treatment for physical ailments, too.
The recent tragic mass shootings have refocused efforts to treat gun violence as a public health issue rather than strictly a law enforcement problem. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Mary Agnes Carey of Kaiser Health News join KHN鈥檚 Julie Rovner to discuss this, plus the health implications of the budget deal passed by Congress and signed by President Donald Trump, as well as reaction from Canada to a proposal to allow broader imports of its prescription drugs. Plus, for 鈥渆xtra credit,鈥 the panelists recommend their favorite health stories of the week.
The drug CroFab, which has been on the market since 2000, now faces competition from a drug called Anavip. But both are expensive.
A federal advisory panel says people between ages 27 and 45 may benefit from the vaccine to fight the human papillomavirus. But some public health advocates worry that the advice doesn鈥檛 provide doctors and patients clear guidance about who in this large age group are good candidates for the vaccine.
A case of questionable logic.
After journalists investigate, Fresenius, one of the largest dialysis providers in the U.S., has agreed to waive a half-million-dollar bill. Sovereign Valentine, from Plains, Mont., said it鈥檚 a 鈥渉uge relief.鈥
漏 2026 麻豆女优